RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. - Wikidata - wikimedia - TriplyDB

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.

http://www.wikidata.org/entity/Q43583328

about

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.RET gene abnormalities and thyroid disease: who should be screened and when Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.The role of podoplanin in the biology of differentiated thyroid cancers.Thyroid cancer: current molecular perspectives.The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer Multi-targeted approach in the treatment of thyroid cancer.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells.RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.Modulation of sodium iodide symporter in thyroid cancer Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.Drosophila Cancer Models Identify Functional Differences between Ret Fusions.Oxidoreductase interactions include a role for ERp72 engagement with mutant thyroglobulin from the rdw/rdw rat dwarf.Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells Thyroid carcinoma: molecular pathways and therapeutic targets The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.Single photon emission computed tomography imaging for temporal dynamics of thyroidal and salivary radionuclide accumulation in 17-allyamino-17-demothoxygeldanamycin-treated thyroid cancer mouse model.Clinicopathologic and molecular disease prognostication for papillary thyroid cancer.Clinical implications of molecular markers in follicular cell-derived thyroid cancer.Teaching an old dogma new tricks: twenty years of Shc adaptor signalling.Signaling adaptor ShcD suppresses extracellular signal-regulated kinase (Erk) phosphorylation distal to the Ret and Trk neurotrophic receptors.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.Somatostatin activates Ras and ERK1/2 via a G protein βγ-subunit-initiated pathway in thyroid cells.Ras oncoprotein disrupts the TSH/CREB signaling upstream adenylyl cyclase in human thyroid cell.mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.Genetics of papillary thyroid cancer initiation: implications for therapy New targeted molecular therapies for dedifferentiated thyroid cancer.Candidate agents for papillary thyroid cancer identified by gene expression analysis.An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.

P2860

Q24519206-6421ED61-F86D-48C5-A699-8FBF2F679E43 Q24596266-DCE7B1FB-37C7-42F0-AF32-D3F72923432E Q24652758-44E623C7-876A-418D-84BE-7892AD71F115 Q27824825-C2C45D53-EEC1-4BB6-948D-6CBFE2693C16 Q28709562-7FB23412-2370-4188-A79A-DC8ABF3F2D15 Q33193878-F36C6D67-8E67-4614-8C49-2E451367C043 Q33568168-870C11BB-1CEC-49BB-82DC-2FE97094B441 Q33760910-7D6CED7A-F908-4FEB-8C8B-0FE780DFEC0A Q33770842-76C941A6-1DA2-4A11-A08C-E321F1931446 Q33982413-86AE0923-EBEC-4A60-A4FC-E5826C72A9C5 Q34109756-CA75A3A0-23C0-4E08-BFBE-20EBB0B85256 Q34533804-7E11EDC4-7370-4386-83FD-0AB05A02536D Q34578515-40B571C9-B7F2-485B-88DC-5349B41ED3EA Q35124840-E2090C2C-30F8-47BE-B097-AF5826EA750B Q35437491-C5D5663E-93F4-4253-8FEA-63EE0C04BB94 Q35578577-4BEA6F2D-9064-4916-A6EB-1D875C4FBF3A Q35690173-60D9D15B-1785-4ED1-829C-71AC2813A27B Q35763320-04513BF8-1DE9-49D8-9A38-7D1F3E524F13 Q35977327-DB3777B5-DEAB-45C4-B233-BA679A41D051 Q36132331-3D0E4749-68C6-4E4C-BB5A-B800B39B6111 Q36890014-FB4DCAC5-718A-4210-A81E-41B1E11E276F Q37035285-77C42D07-1A10-43DC-B17F-2E00530282DD Q37035505-91DCC3FF-6C4A-4A18-BD9D-B7C8E3B4628D Q37078783-3C39B6B5-1B58-4C53-A7B2-DC1A2EF17852 Q37147768-74A0F434-B4F4-4403-BF31-D7264029D9FD Q37351482-E6798B47-D4CC-42F3-BFD1-C8350C66DE23 Q37518427-C1DAB7F9-8150-432D-9929-191F56DC5390 Q37598938-3445BD71-100F-4E00-B379-E8B883B083B3 Q37611825-C2D55AED-43B4-41E1-AEB8-0C24CA88DF4E Q38042699-FDFABF42-2B0C-4E39-B6DE-6E29AF3241DD Q38715948-26DF1F0D-004B-4FA7-8033-6BF425E900C4 Q38823954-1F2FF76A-E700-4E95-A4F3-A2EDE8EA1CE0 Q38827518-194E8A3D-D20B-40F3-8114-E5594B5DF712 Q38995868-2C2E3492-C47C-4EA9-B1A9-210C9BC25B4D Q39006509-7130A456-AB7D-4EFE-8EB2-F5AFC2D7723F Q39350519-A9E81C82-2131-4B45-9CF8-26FAC90306F5 Q41908055-0F29F95F-AF49-42FF-BEED-BAD94C0462F2 Q42734670-4DE06D03-8C01-4AA5-AE11-1F8FD44905B5 Q43548418-B33ECC2F-6EF1-4641-BCBA-414F84C68AE8 Q44116793-18F02B46-0233-4CAE-82B8-AD9826E2A7BD

P2860

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.

http://www.wikidata.org/entity/Q43583328

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.

@en

RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.

@nl

type

label

RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.

@en

RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.

@nl

prefLabel

RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.

@en

RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.

@nl

P1433

Q43583328-4B9E5BB5-90FD-4D23-AF88-32D752E3F563

P1476

Q43583328-E6A05496-71D8-47BE-9578-8520DD9DDD7D

P2093

Q43583328-314383E7-78A7-4648-BB8E-642A1014EDBF

Q43583328-63EDF27C-3902-458A-A122-28A31167A2CF

Q43583328-6C88A1E9-C8C3-4169-AB74-E1E6491C35EB

Q43583328-E53DE326-5F62-4865-9391-CC1300CFC104

P2860

Q43583328-030F4252-90F3-47D2-9AA8-AEBB284C0E7A

Q43583328-062F8925-BAB1-4149-B57F-1D31E8578F04

Q43583328-1EC78BED-558A-4975-9CE4-532FB5850529

Q43583328-2494BBBB-BE30-4005-94BC-B0CEA01EC183

Q43583328-29AF4083-3A4F-43AA-BA1E-AA2F5E895A3C

Q43583328-2F811455-0D11-4D2C-A3C0-CB82A123239A

Q43583328-3035E1DE-CA80-4155-874B-54B98E1CF916

Q43583328-30857EC8-5746-40F5-9C23-CA01D9039EBC

Q43583328-3498D297-400C-4948-B658-C41DB5448FE1

Q43583328-5E5941CF-8345-4571-96D9-B83FE402022C

P2888

Q43583328-3E5A75B1-5C71-4814-9412-BEAD9FE5A46E

P304

Q43583328-6032A37B-FB45-4C60-9C9D-870C2AA20283

P31

Q43583328-71AEC396-E72F-4F13-8074-A55805435AF1

P356

Q43583328-AC1A8C48-A611-4214-9C48-0E60C1F3AD91

P407

Q43583328-A9925D92-BB57-4B68-97FB-92A3D7C59CCF

P433

Q43583328-63084E7B-6400-40E6-B137-BC1B031FEF06

P478

Q43583328-4764221A-7B3C-46DC-BF20-21BD89920064

P577

Q43583328-7FF4EB24-DF48-46B0-9903-E729BAF7E599

P5875

Q43583328-BE3E07F4-5CBD-4C37-9969-917786F1AE6E

P6179

Q43583328-3717C8F0-9E0C-42B4-A9C6-BCE5AE611E54

P698

Q43583328-41798D61-E919-4FBF-8ABA-5C41F1CD5DBA

P356

P1433

P1476

RET/PTC-induced dedifferentiat ...... ng through SHC-RAS-MAP kinase.

@en

P2093

Hiroaki Kuroda

http://www.w3.org/2001/XMLSchema#string

James A Fagin

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Knauf

http://www.w3.org/2001/XMLSchema#string

Saswata Basu

http://www.w3.org/2001/XMLSchema#string

P2860

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma

Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade

Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1

The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities

Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7

The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10

Transcriptional activation by tetracyclines in mammalian cells

P2888

P304

4406-4412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1206602

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10667833

http://www.w3.org/2001/XMLSchema#string

P6179

1018892721

http://www.w3.org/2001/XMLSchema#string

P698

12853977

http://www.w3.org/2001/XMLSchema#string